Neoadjuvant immunotherapy for advanced gastric cancer:current advances and future prospects
10.12354/j.issn.1000-8179.2025.20250492
- VernacularTitle:进展期胃癌新辅助免疫治疗的突破与展望
- Author:
Zhang LEI
1
;
Luo SIQI
;
Qi HONGBIN
;
Jin XIANGREN
;
Dai LI
;
Wang HAIBIN
;
He TONG
Author Information
1. 贵州医科大学附属医院胃肠外科(贵阳市 550000)
- Publication Type:Journal Article
- Keywords:
stomach neoplasms;
immune checkpoint inhibitors;
biomarkers;
neoadjuvant therapy;
tumor microenvironment
- From:
Chinese Journal of Clinical Oncology
2025;52(13):697-702
- CountryChina
- Language:Chinese
-
Abstract:
This review summarizes recent advances in neoadjuvant immunotherapy for advanced gastric cancer.Through literature search in PubMed,Web of Science,and CNKI databases from 2020 to 2023,we systematically analyzed the mechanisms,clinical applications,and bio-marker research.Programmed death-1(PD-1)inhibitors combined with chemotherapy significantly improve patient outcomes,while mi-crosatellite instability(MSI),programmed death-ligand 1(PD-L1)expression,and tumor mutational burden(TMB)have been identified as important predictive biomarkers.Multi-omics analysis shows great potential in identifying optimal responders,with pyroptosis-related gene scoring system(PRS)positively correlating with anti-tumor immune infiltration.Metabolic reprogramming and epigenetic regulation in the tumor microenvironment play key roles in immune evasion,while emerging targets such as Claudin 18.2 and combination targeting strategies further enhance therapeutic efficacy.Despite significant progress,precise patient selection and overcoming resistance mechan-isms remain major challenges.Future research should focus on biomarker validation,personalized treatment strategy development,tumor microenvironment dynamic analysis,and novel combination therapy exploration to improve clinical outcomes.
